

ASX RELEASE

6 February 2020

### **Appointment of Dr. John Lambert as Managing Director**

Amplia Therapeutics Limited (“Amplia”, the “Company”), announces the appointment of CEO Dr. John Lambert as Managing Director of the Company. The appointment is effective from 6 February 2020.

Amplia Chairman Dr. Warwick Tong stated, “John has done a stellar job since his appointment as CEO in terms of moving ahead our upcoming clinical programs and setting the commercial strategy for the Company, in close consultation with the founders, Board and external medical advisors. The appointment of John as a Director reflects our confidence in his execution performance, integrity and his contribution to the governance of the Company.”

Dr. Lambert’s remuneration is unchanged from its current level as CEO (refer ASX Announcement - 24 June 2019).

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics Limited.

- End -

#### **For Further Information**

Dr. John Lambert  
CEO & Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

#### **About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).